277 related articles for article (PubMed ID: 27909582)
1. Ebola research funding: a systematic analysis, 1997-2015.
Fitchett JR; Lichtman A; Soyode DT; Low A; Villar de Onis J; Head MG; Atun R
J Glob Health; 2016 Dec; 6(2):020703. PubMed ID: 27909582
[TBL] [Abstract][Full Text] [Related]
2. Knowledge and attitude towards Ebola and Marburg virus diseases in Uganda using quantitative and participatory epidemiology techniques.
Nyakarahuka L; Skjerve E; Nabadda D; Sitali DC; Mumba C; Mwiine FN; Lutwama JJ; Balinandi S; Shoemaker T; Kankya C
PLoS Negl Trop Dis; 2017 Sep; 11(9):e0005907. PubMed ID: 28892520
[TBL] [Abstract][Full Text] [Related]
3. [Marburg and Ebola hemorrhagic fevers--pathogens, epidemiology and therapy].
Stock I
Med Monatsschr Pharm; 2014 Sep; 37(9):324-30; quiz 331-2. PubMed ID: 25282746
[TBL] [Abstract][Full Text] [Related]
4. Sequencing ebola and marburg viruses genomes using microarrays.
Hardick J; Woelfel R; Gardner W; Ibrahim S
J Med Virol; 2016 Aug; 88(8):1303-8. PubMed ID: 26822839
[TBL] [Abstract][Full Text] [Related]
5. Catching Chances: The Movement to Be on the Ground and Research Ready before an Outbreak.
Brett-Major D; Lawler J
Viruses; 2018 Aug; 10(8):. PubMed ID: 30126221
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions.
Bausch DG; Sprecher AG; Jeffs B; Boumandouki P
Antiviral Res; 2008 Apr; 78(1):150-61. PubMed ID: 18336927
[TBL] [Abstract][Full Text] [Related]
7. Lessons learned during active epidemiological surveillance of Ebola and Marburg viral hemorrhagic fever epidemics in Africa.
Allaranga Y; Kone ML; Formenty P; Libama F; Boumandouki P; Woodfill CJ; Sow I; Duale S; Alemu W; Yada A
East Afr J Public Health; 2010 Mar; 7(1):30-6. PubMed ID: 21413569
[TBL] [Abstract][Full Text] [Related]
8. Drug targets in infections with Ebola and Marburg viruses.
Gene OG; Julia BE; Vanessa MR; Victoria WJ; Thomas GW; Lisa HE
Infect Disord Drug Targets; 2009 Apr; 9(2):191-200. PubMed ID: 19275706
[TBL] [Abstract][Full Text] [Related]
9. Ebola and Marburg viruses: pathogenesis and development of countermeasures.
Hensley LE; Jones SM; Feldmann H; Jahrling PB; Geisbert TW
Curr Mol Med; 2005 Dec; 5(8):761-72. PubMed ID: 16375711
[TBL] [Abstract][Full Text] [Related]
10. The allocation of USdollar;105 billion in global funding from G20 countries for infectious disease research between 2000 and 2017: a content analysis of investments.
Head MG; Brown RJ; Newell ML; Scott JAG; Batchelor J; Atun R
Lancet Glob Health; 2020 Oct; 8(10):e1295-e1304. PubMed ID: 32971052
[TBL] [Abstract][Full Text] [Related]
11. Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.
Suschak JJ; Schmaljohn CS
Hum Vaccin Immunother; 2019; 15(10):2359-2377. PubMed ID: 31589088
[TBL] [Abstract][Full Text] [Related]
12. Ebola and Marburg haemorrhagic fever viruses: major scientific advances, but a relatively minor public health threat for Africa.
Leroy EM; Gonzalez JP; Baize S
Clin Microbiol Infect; 2011 Jul; 17(7):964-76. PubMed ID: 21722250
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol-conjugated stapled peptides inhibit Ebola and Marburg viruses in vitro and in vivo.
Pessi A; Bixler SL; Soloveva V; Radoshitzky S; Retterer C; Kenny T; Zamani R; Gomba G; Gharabeih D; Wells J; Wetzel KS; Warren TK; Donnelly G; Van Tongeren SA; Steffens J; Duplantier AJ; Kane CD; Vicat P; Couturier V; Kester KE; Shiver J; Carter K; Bavari S
Antiviral Res; 2019 Nov; 171():104592. PubMed ID: 31473342
[TBL] [Abstract][Full Text] [Related]
14. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
[TBL] [Abstract][Full Text] [Related]
15. Marburg and Ebola virus infections in laboratory non-human primates: a literature review.
Schou S; Hansen AK
Comp Med; 2000 Apr; 50(2):108-23. PubMed ID: 10857001
[TBL] [Abstract][Full Text] [Related]
16. Drivers of African Filovirus (Ebola and Marburg) Outbreaks.
Stephens PR; Sundaram M; Ferreira S; Gottdenker N; Nipa KF; Schatz AM; Schmidt JP; Drake JM
Vector Borne Zoonotic Dis; 2022 Sep; 22(9):478-490. PubMed ID: 36084314
[TBL] [Abstract][Full Text] [Related]
17. [Ebola vaccine and treatment].
Takada A
Uirusu; 2015; 65(1):61-70. PubMed ID: 26923959
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial.
Kibuuka H; Berkowitz NM; Millard M; Enama ME; Tindikahwa A; Sekiziyivu AB; Costner P; Sitar S; Glover D; Hu Z; Joshi G; Stanley D; Kunchai M; Eller LA; Bailer RT; Koup RA; Nabel GJ; Mascola JR; Sullivan NJ; Graham BS; Roederer M; Michael NL; Robb ML; Ledgerwood JE;
Lancet; 2015 Apr; 385(9977):1545-54. PubMed ID: 25540891
[TBL] [Abstract][Full Text] [Related]
19. [Ebola hemorrhagic fever and Marburg virus disease: their virological and clinical aspects].
Hirabayashi Y
Ryoikibetsu Shokogun Shirizu; 1999; (23 Pt 1):85-9. PubMed ID: 10088344
[No Abstract] [Full Text] [Related]
20. Treatment of ebola virus disease.
Kilgore PE; Grabenstein JD; Salim AM; Rybak M
Pharmacotherapy; 2015 Jan; 35(1):43-53. PubMed ID: 25630412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
